Jazz Pharmaceuticals plc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.90%.
Did JAZZ Beat Earnings? Q3 2025 Results
Jazz Pharmaceuticals delivered a standout third quarter, posting adjusted earnings of $8.13 per diluted share against a consensus estimate of $5.85, a beat of nearly 39%, while revenue of $1.13 billion edged past expectations by 1.58% and climbed 6.7% year over year. The quarter marked a record revenue performance for the company, with its neuroscience franchise supplying most of the momentum; Xywav grew 11% to $431.40 million and Epidiolex surged 20% to $302.60 million on strong volume and favorable pricing dynamics. Two FDA approvals added strategic depth, including the accelerated green light for Modeyso in a rare brain tumor indication, which generated $11.00 million in its initial partial quarter on shelves. GAAP results were weighed down by a combined $151.50 million in litigation settlements and a $42.50 million acquired IPR&D charge, though a $205.90 million tax benefit softened the blow. Looking ahead, management raised its full-year adjusted EPS guidance to $7.65 to $8.45, even as some observers note the stock's below-industry valuation reflects lingering questions about longer-term revenue trajectory.
- Epidiolex 20% net product sales growth driven by 10% volume increase and lower U.S. gross-to-net deductions
- Xywav 11% net product sales growth with approximately 450 net patient adds in the quarter
- Modeyso launched in August 2025 with strong initial uptake generating $11.0 million in first partial quarter
- Total neuroscience revenue increased 9% to $827.4 million including royalties
- Non-GAAP adjusted gross margin of 92.2%
- $205.9 million income tax benefit from recognition of Chimerix-acquired U.S. deferred tax assets
“Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our team. We were pleased to once again deliver solid execution across our sleep, epilepsy and oncology portfolios, led by double-digit percentage growth from Epidiolex and Xywav.”
Jazz Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Jazz Pharmaceuticals narrowed its 2025 total revenue guidance to $4.175–$4.275 billion (from $4.150–$4.300 billion). GAAP net loss guidance was updated to $(435)–$(315) million, or $(7.10)–$(5.20) per diluted share. Non-GAAP adjusted net income guidance was raised to $475–$525 million, or $7.65–$8.45 per diluted share (from $300–$350 million or $4.80–$5.60). Non-GAAP adjusted gross margin is projected at 92%. Top-line PFS data from the Phase 3 HERIZON-GEA-01 trial of zanidatamab in first-line gastroesophageal adenocarcinoma is expected in Q4 2025. The guidance includes approximately $947.9 million in acquired IPR&D expenses, $323.5 million in litigation settlements, and a $205.9 million income tax benefit.
JAZZ YoY Financials
JAZZ Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.